Clene Inc. Updates Registration for Common Stock & Warrants

TL;DR

**Clene Inc. just filed an 8-K to keep its stock and warrants properly registered on Nasdaq.**

AI Summary

Clene Inc. filed an 8-K on January 8, 2024, to update its registration statement for its Common Stock ($0.0001 par value) and Warrants, which allow holders to acquire one-half of one share of Common Stock for $11.50 per share. This filing ensures that the company's securities remain properly registered and tradable on The Nasdaq Capital Market. For investors, this matters because it confirms the continued compliance and liquidity of CLNN shares and warrants, which is crucial for their ability to buy or sell these securities.

Why It Matters

This filing ensures Clene Inc.'s securities remain compliant with SEC regulations, maintaining their tradability on The Nasdaq Capital Market.

Risk Assessment

Risk Level: low — This is a routine compliance filing and does not indicate any new financial or operational risks for the company.

Analyst Insight

This filing is a routine compliance update, so investors should not expect any immediate price movement based solely on this information. It confirms the continued tradability of CLNN shares and warrants on Nasdaq, which is a positive for market liquidity and investor confidence in the company's regulatory adherence.

Key Numbers

• $0.0001 — Common Stock Par Value (The stated par value of Clene Inc.'s common stock.)
• $11.50 — Warrant Exercise Price (The price at which one-half of one share of common stock can be acquired via warrants.)

Key Players & Entities

• Clene Inc. (company) — the registrant filing the 8-K
• $0.0001 (dollar_amount) — par value of Common Stock
• $11.50 (dollar_amount) — per share exercise price for warrants
• January 8, 2024 (date) — date of earliest event reported and filing date
• The Nasdaq Capital Market (company) — exchange where securities are registered

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value   CLNN   Th
• $11.50 — e-half of one share of Common Stock for $11.50 per share   CLNNW   The

Filing Documents

• clnn20240104_8k.htm (8-K) — 31KB
• ex_612353.htm (EX-99.1) — 23KB
• ex_612355.htm (EX-99.2) — 20KB
• slide01.jpg (GRAPHIC) — 44KB
• slide02.jpg (GRAPHIC) — 104KB
• slide03.jpg (GRAPHIC) — 57KB
• slide04.jpg (GRAPHIC) — 55KB
• slide05.jpg (GRAPHIC) — 49KB
• slide06.jpg (GRAPHIC) — 73KB
• slide07.jpg (GRAPHIC) — 46KB
• slide08.jpg (GRAPHIC) — 61KB
• slide09.jpg (GRAPHIC) — 70KB
• slide10.jpg (GRAPHIC) — 63KB
• slide11.jpg (GRAPHIC) — 64KB
• slide12.jpg (GRAPHIC) — 63KB
• slide13.jpg (GRAPHIC) — 63KB
• slide14.jpg (GRAPHIC) — 58KB
• slide15.jpg (GRAPHIC) — 56KB
• slide16.jpg (GRAPHIC) — 65KB
• slide17.jpg (GRAPHIC) — 77KB
• slide18.jpg (GRAPHIC) — 60KB
• slide19.jpg (GRAPHIC) — 51KB
• slide20.jpg (GRAPHIC) — 60KB
• slide21.jpg (GRAPHIC) — 54KB
• slide22.jpg (GRAPHIC) — 57KB
• slide23.jpg (GRAPHIC) — 75KB
• slide24.jpg (GRAPHIC) — 67KB
• slide25.jpg (GRAPHIC) — 65KB
• slide26.jpg (GRAPHIC) — 65KB
• slide27.jpg (GRAPHIC) — 65KB
• slide28.jpg (GRAPHIC) — 59KB
• slide29.jpg (GRAPHIC) — 65KB
• slide30.jpg (GRAPHIC) — 70KB
• slide31.jpg (GRAPHIC) — 63KB
• slide32.jpg (GRAPHIC) — 46KB
• slide33.jpg (GRAPHIC) — 82KB
• slide34.jpg (GRAPHIC) — 20KB
• 0001437749-24-000815.txt ( ) — 3117KB
• clnn-20240108.xsd (EX-101.SCH) — 4KB
• clnn-20240108_def.xml (EX-101.DEF) — 14KB
• clnn-20240108_lab.xml (EX-101.LAB) — 18KB
• clnn-20240108_pre.xml (EX-101.PRE) — 14KB
• clnn20240104_8k_htm.xml (XML) — 5KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure.   In connection with the press release discussed under Item 8.01 in this Current Report on Form 8-K, on January 8, 2024, Clene Inc. (the "Company") released an updated corporate presentation (the "Corporate Presentation") on its website, invest.clene.com. A copy of the Corporate Presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The Company plans to use its website to disseminate future updates to the Corporate Presentation and may not file or furnish a Current Report on Form 8-K alerting investors if the Corporate Presentation is updated.   The information furnished in this Item 7.01, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act"), as amended, or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by the Company under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in any such filings, except as shall be expressly set forth by specific reference in such a filing.  

01 Other Events

Item 8.01 Other Events.   On January 8, 2024, the Company issued a press release announcing significant improvement in vision and cognition with CNM-Au8 treatment in the VISIONARY-MS trial long-term open label extension. A copy of the press release is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.  

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits.   (d) Exhibits   Exhibit Number   Exhibit Description 99.1   Corporate Presentation. 99.2   Press Release, dated January 8, 2024, announcing significant improvement in vision and cognition with CNM-Au8 treatment in VISIONARY-MS trial long-term open label extension. 104   Cover Page Interactive Data File (formatted as Inline XBRL).   1  

SIGNATURES

SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.           CLENE INC.     Date: January 8, 2024 By: /s/ Robert Etherington     Robert Etherington     President and Chief Executive Officer     2    

View Full Filing

View this 8-K filing on SEC EDGAR